Stocklytics Platform
Asset logo for symbol ALLK
Allakos
ALLK55
$0.97arrow_drop_down4.93%-$0.05
Penny Stock
Asset logo for symbol ALLK
ALLK55

$0.97

arrow_drop_down4.93%

Performance History

Chart placeholder
Key Stats
Open$1.02
Prev. Close$1.03
EPS-2.03
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$87.48M
PE Ratio-
LOWHIGH
Day Range0.94
1.07
52 Week Range0.54
3.41
Ratios
Revenue-
EBITDA Margin %-
EPS-2.03

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Allakos (ALLK)

Allakos Inc (ALLK) is a clinical stage biotechnology company that specializes in the development of therapeutic antibodies for the treatment of various allergic and inflammatory diseases. The company's lead product candidate is AK002, which is being evaluated for the treatment of eosinophilic gastritis and eosinophilic duodenitis, conditions characterized by an excessive accumulation of eosinophils in the stomach and duodenum. AK002 is also being studied for the treatment of allergic conjunctivitis and allergic asthma. The company has a strong pipeline of other product candidates targeting different diseases.
ALLK stock has had a volatile price history since the company went public in 2018. It initially gained significant attention from investors due to the potential of its unique antibody therapies. However, the stock price has experienced fluctuations in response to clinical trial results and market sentiment. It is important for investors to carefully analyze the company's financials and the progress of its clinical trials to make informed investment decisions.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Robert Alexander Ph.D.
Headquarters
San Carlos
Employees
123
Exchange
NASDAQ
add Allakos  to watchlist

Keep an eye on Allakos

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the market capitalization of Allakos (ALLK)?

Allakos (ALLK) has a market capitalization of $87.49M. The average daily trading volume is 0.99, indicating the stock's liquidity and investor engagement.
help

What is Allakos 's (ALLK) price per share?

The current price per share for Allakos (ALLK) is $0.98. The stock has seen a price change of -$0.05 recently, indicating a -4.93% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Allakos (ALLK)?

For Allakos (ALLK), the 52-week high is $3.41, which is 248.24% from the current price. The 52-week low is $0.54, the current price is 81.33% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Allakos (ALLK) a growth stock?

Allakos (ALLK) has shown an average price growth of -1.65% over the past three years. It has received a score of 3 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Allakos as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Allakos (ALLK) stock price performance year to date (YTD)?

As of the latest data, Allakos (ALLK) has a year-to-date price change of -19.07%. Over the past month, the stock has experienced a price change of -14.85%. Over the last three months, the change has been 50.62%. Over the past six months, the figure is 19.96%. Looking at a longer horizon, the five-year price change stands at -98.89%.
help

Is Allakos (ALLK) a profitable company?

Allakos (ALLK) has a net income of -$185.7M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$196.06M. Furthermore, the EBITDA is -$154.72M.

Take Your Investments to a Whole New Level